Conformis, Inc. (CFMS)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Conformis, Inc. (CFMS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Conformis, Inc. (“Conformis” or the Company”) (NASDAQ: CFMS). The investigation concerns whether Conformis and certain of its officers and/or directors have violated federal securities laws.
On July 31, 2019, post-market, Conformis announced its financial results for the second quarter of 2019. Conformis advised investors that it was “updating its 2019 expectations and now expects generally flat year-over-year product revenue growth for the full year 2019.” Conformist stated that its “expected decrease in growth in the second half of the year is due primarily to denials of coverage from Aetna, the third largest commercial payor.” On this news, Conformis’s stock price fell sharply during intraday trading on August 1, 2019.
If you are aware of any facts relating to this investigation, or purchased Conformis shares, you can learn more about the investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.